The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients Riccardo Levi<sup>1,2</sup>\*, Leonardo Ubaldi<sup>1,2</sup>\*, Chiara Pozzi<sup>2</sup>, Giovanni Angelotti<sup>2</sup>, Maria Teresa Sandri<sup>1,2</sup>, Elena Azzolini<sup>1,2</sup>, Michela Salvatici<sup>2</sup>, Victor Savevski<sup>2</sup>, Alberto Mantovani<sup>1,2,3</sup> and Maria Rescigno<sup>1,2,#</sup> <sup>1</sup>Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini, 20072 Pieve Emanuele, MI, Italy. <sup>2</sup>IRCCS Humanitas Clinical and Research Center, Via Manzoni 56, 20089 Rozzano, MI, Italy. <sup>3</sup>The William Harvey Research Institute, Queen Mary University of London, London, UK \*These authors contributed equally to the work \*Corresponding author E-mail: maria.rescigno@hunimed.eu **Humanitas University** Via Rita Levi Montalcini, 4 20072 Pieve Emanuele (MI) Italy 

## Abstract

 The factors involved in the persistence of antibodies to SARS-CoV-2 are unknown. We evaluated the antibody response to SARS-CoV-2 in personnel from 10 healthcare facilities and its association with individuals' characteristics and COVID-19 symptoms in an observational study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8-10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. In individuals positive for IgG ( $\geq 12$  AU/mL) at the beginning of the study, we found an increase [p = 0.0002] in antibody response in symptomatic subjects, particularly with anosmia/dysgeusia (OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.

#### Introduction

43

44

45 46

47

48 49

50

51

52

53

54

55

56

57

58

59

60

61 62

63

64

65

66

67

68

69

70

71

72 73

74

75

76

It is becoming clear that the antibody response to SARS-CoV-2 can last at least 6 months in symptomatic patients <sup>1</sup>, but it seems to decline in asymptomatics <sup>2</sup>. Similarly, a reduction of antibody response in asymptomatic individuals was shown in a study with a fewer number of individuals (n = 37) <sup>3</sup>. The antibody response in COVID-19 patients is associated with the establishment of a memory B cell response which is higher at 6 months <sup>1</sup>, however, it is not clear whether there are features that correlate with this sustained B cell response. We previously showed that an anti-SARS-CoV-2 serological analysis allowed us to follow the diffusion of the virus within healthcare facilities in areas differently hit by the virus <sup>4</sup>. At 8-10 months of distance, we analyzed the duration of this antibody response and evaluated whether there were features correlating with maintenance, reduction or increase of the antibody response.

#### Results

We analyzed the persistence of the antibody response in healthcare workers that underwent immunological surveillance for SARS-CoV-2 exposure and resulted positive for anti-Spike 1/2 IgG  $(IgG \ge 12 \text{ AU/mL})$ . Although the test manufacturer considers positive subjects above 15 AU/mL and equivocal those between 12 and 15 (AU/mL), based on our previous publication showing that these two groups behaved very similarly we considered positive everybody  $\geq 12 \text{ AU/mL}^4$ . The accrual was on a voluntary basis and did not occur in the symptomatic phase (at around 43 +/- 17 days from COVID-19 assessment when symptomatic). We excluded all of the individuals that became positive over the course of the analysis so to focus only on those individuals that were exposed during the first wave of infection to evaluate the duration of the antibody response. We assessed the correlation of the rate of antibody increase or decrease with the different analyzed features for the first two time points of observation in subjects with  $IgG \ge 12$  AU/mL. In Tables 1 and 2 are reported the rates for individual classes of features with relative statistical analysis. As shown, females sustained the antibody response better than males (p = 0.01); similarly non-medical healthcare professionals (specifically, healthcare partner operators) had higher antibody rates (p =0.0009). The levels of antibodies increased in hospitals located in the Bergamo area (Castelli and Gavazzeni p < 0.0001) (Table 1) which was more hit by COVID-19 (37 – 43% of individuals with  $IgG \ge 12$ ) <sup>4</sup>. More important, the IgG rate in individuals which were positive for IgG ( $IgG \ge 12$ ) AU/mL; n = 613) at the beginning of the study was increased (p < 0.000001) over time, and this increase was either minor in asymptomatics (n = 91, p = 0.00003) and paucisymptomatics (n = 203) or strong in symptomatics (n = 319, p = 0.0006) (Table 2). This may explain why individuals from hospitals in the Bergamo area or non-medical healthcare professionals had higher levels of

77 antibodies as most of them suffered from symptomatic COVID-19 (59% and 73%, respectively). 78 On the contrary, those that had an intermediate IgG titer (3.8 < IgG < 12 AU/mL considered as 79 negative) displayed all a significant reduction in IgG rate (p < 0.000001) (Table 1). However, this 80 population is considered as negative for SARS-CoV-2 IgG according to manufacturer. Many 81 symptoms, including fever, cough, muscle pain, asthenia, tachycardia and anosmia/dysgeusia, 82 correlated with an increase of antibodies in the first two time points of observation (Table 2). 83 As we noticed that the distribution of the rate feature presented a high value of kurtosis (see methods) we restricted the data set to subjects with IgG rates either below the 10<sup>th</sup> percentile [< -84 0.033 (n = 454)] or above the 90<sup>th</sup> percentile [> 0.005 (n = 445)] to prevent a bias-variance problem 85 in machine learning models. The accuracy of these rates was confirmed by a linear regression 86 87 analysis. In Figure 1a and 1b are shown the regression diagnostic plots of predicted values against 88 residuals of training and test data according to the threshold (< -0.033 AU/ml\*day and > 0.005 89 AU/ml\*day). In Table 3 is shown the Chi-squared analysis for the populations below or above the 90 set threshold rates. We found that as for the previous analysis, males reduced the level of antibodies 91 more than females, even though this difference was no longer statistically significant (p = 0.06). 92 The levels of antibodies increased in hospitals located in the Bergamo area (Castelli and Gayazzeni: p = 0.0032 and p = 0.0005, respectively) which was more hit by COVID-19 (37 - 43% of 93 individuals with  $IgG \ge 12$ ) and most of the individuals were symptomatic <sup>4</sup> while it decreased in 94 95 Humanitas Rozzano (p=0.0806) which was less heavily hit (10% of individuals with IgG  $\geq$  12) and had less symptomatic individuals <sup>4</sup> (Table 3). The rate decreased in asymptomatic (65% of subjects 96 97 fell in the group < -0.033; p < 0.000001), remained constant in paucisymptomatic and increased in 98 symptomatic individuals (62% of subjects were in the group > 0.005; p < 0.000001) (Table 4). 99 Interestingly, among the different symptoms, fever, cough, muscle pain, asthenia, dyspnea, 100 tachycardia, chest pain and anosmia/dysgeusia all correlated with a higher number of individuals 101 falling into the group with rate > 0.005, indicating that these symptoms were strongly associated 102 with sustained/increased antibody response (0.000001 , Table 4 and Suppl. Fig. 1).103 Among these, anosmia/dysgeusia was associated with the highest percentage of subjects presenting 104 with increased IgG rate (69%; p < 0.000001, Table 4 and Suppl. Fig. 1). Having observed 105 differences according to sex, role and site, and since many symptoms are linked, we performed a 106 multivariate statistical analysis based on a supervised machine learning classification approach (see 107 methods). Through a Bayesian hyperparameter optimization algorithm, we assessed that the best 108 machine learning model is a Bagging classifier of 7 logistic regression, which was evaluated both 109 on a training (Accuracy = 76.26; ROC AUC = 76.30; Recall = 81.14) and a test dataset (Accuracy = 110 72.00; ROC AUC = 72.12; Recall = 81.08), where the training/test split is 80%-20%, stratified by

111 outcome. Classification metrics on training set and test set are comparable, which shows that the 112 model does not present overfitting on training data. In Figure 1c is shown the multivariate logistic 113 regression analysis. We found that the increased rate was associated primarily with 114 anosmia/dysgeusia (regression coefficient=1.0, 95% CI 0.56 – 1.46) and with chest pain (regression 115 coefficient=0.84, 95% CI 0.24 - 1.44), while the decreased rate was associated to subjects with 116 intermediate IgG (3.8 < IgG < 12) (regression coefficient = -1.61, 95% CI -2.03 - -1.0), which may 117 be related to a noise in the instrument testing, and with past neoplasia (regression coefficient = -1.38, 95% CI -2.4 – -0.37). Interestingly, 54% of subjects with chest pain also presented loss of 118 119 smell/taste while only 22% of subjects with smell/taste dysfunction also had chest pain, suggesting 120 that IgG increase in the symptomatic population is primarily linked to anosmia and dysgeusia (not 121 shown). In figure 1d are shown the odds ratio relative to figure 1c, which for chest pain is 2.32 122 (95% CI 1.27 – 4.24), for anosmia/dysgeusia is 2.75 (95% CI 1.75 – 4.30), for subjects with 123 intermediate IgG (3.8 < IgG < 12) is 0.2 (95% CI 0.13 - 0.30) and for subjects with past neoplasia 124 is 0.25 (95% CI 0.09 – 0.69). Overall, these results indicate that although many symptoms are 125 associated with an increase of IgG abundance in the observation time, only anosmia/dysgeusia and 126 chest pain are associated to a higher IgG rate in the multivariate logistic regression analysis. By 127 contrast the population with past neoplasia or intermediate levels of IgG (3.8 < IgG < 12 AU/mL) 128 are the ones that display a reduction in IgG. However, the significance of the reduction in the 129 detection of antibodies in subjects with intermediate levels of IgG remains to be investigated, as this 130 population did not represent early infected individuals because they were all nasopharyngeal swab negative <sup>4</sup>. 131 132 We then analyzed whether the antibody response was maintained over time in the third time point 133 of analysis (n = 499) which was evaluated between November and December 2020 thus reaching an 134 observation of 8-10 months. As shown in Figure 2 and Suppl. Fig. 2 we observed that both 135 symptomatic and paucisymptomatic individuals still displayed a higher level of antibodies, however 136 they did not increase between phase 2 and phase 3. By contrast, asymptomatic individuals did not 137 increase their IgG levels over time.

#### Discussion

138139

140

141

142143

144

We analyzed the 8-10-month duration of an antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school (Humanitas University) in Northern Italy in areas differently hit by the virus <sup>4</sup>. We show that the antibody response is stable both in symptomatic and asymptomatic/paucisymptomatic individuals and is increased in females and in non-medical healthcare professionals. Previously, it has been shown in a study conducted in the

146147

148

149150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167168

169

170

171

172173

174

175

176

177

British population that the antibody response declines of nearly 22% in symptomatic individuals and of 64% in asymptomatic individuals <sup>2</sup>. However, this study was based on a prick qualitative test and thus the decline may be related to the sensitivity of the test. We also observed that the antibody response declined when we analyzed the group (3.8 < IgG < 12 AU/mL) with IgG between the limit of detection (3.8 AU/mL) and the threshold of positivity (IgG ≥ 12 AU/mL), as set by manufacturer. Whether this is linked to a difference linked to the sensitivity of the test or to a real reduction in an antibody response that may or may not be specific to SARS-CoV-2, remains to be established. In a previous analysis we excluded that this population represented individuals in the initial phases of an infection as all of them were tested for SARS-CoV-2 by a nasopharyngeal swab which however resulted negative<sup>4</sup>. When we analyzed the extremes, i.e. the individuals with higher rates of antibody increase or decrease (< -0.033 and > 0.005 AU/mL\*day) we observed that asymptomatics had higher negative rates while symptomatics tended to continue increasing the antibody levels suggesting that extreme changes in rate separate the symptomatics from the asymptomatics. As during the observation time there was very limited viral diffusion in Northern Italy, as confirmed also by the finding that only 2 individuals became IgG positive and 2981 remained IgG negative throughout the study (all excluded from the analysis), we can conclude that the sustained or augmented antibody response may not be linked to a re-exposure to the virus. In an attempt to address what improved the antibody response, we found that several symptoms were associated to increased rates of antibodies, however, in a multivariate logistic analysis only anosmia/dysgeusia and chest pain were linked with the highest regression coefficients. Chest pain and anosmia are long-lasting symptoms in COVID-19 patients <sup>5</sup>. In addition, anosmia and/or dysgeusia are very common as they are found in around 50-70% of subjects affected by COVID-19 <sup>6, 7</sup>. In our cohort (Table 2), 49% of IgG positive subjects had anosmia/dysgeusia, 28% chest pain and 13.7% both anosmia/dysgeusia and chest pain, suggesting that indeed these two symptoms may, either alone or in combination, associate with IgG increase. We and others previously found that anosmia/dysgeusia together with fever were the symptoms that mostly characterized SARS-CoV-2 exposure <sup>4, 8</sup>. In agreement, anosmia and dysgeusia have been proposed to be used to track SARS-CoV-2 diffusion <sup>9</sup>. Interestingly, SARS-CoV-2 can infect the olfactory epithelium <sup>10, 11</sup>, including olfactory sensory neurons, support cells and immune cells, that express the viral entry receptors ACE2 and TMPRSS2 10, 12, 13. Here, the virus can persist long and induce local inflammation <sup>11</sup> and olfactory bulb abnormalities <sup>14, 15, 16</sup>. In agreement, the loss of smell and taste can persist in individuals even with RT-PCR SARS-CoV-2 negativity in the nasopharyngeal swab for months <sup>11, 17</sup>. Supporting this possibility, we did not detect any further increase of IgG levels

178 between phase 2 and phase 3 suggesting that when individuals eliminate the virus then there is no 179 further increase of the antibody response. 180 One limitation of our study is that we followed our healthcare workers for the exposure to SARS-181 CoV-2 via measuring the anti S1/S2 IgG response and have not evaluated any other antibody 182 subtype nor their neutralizing activity, even though the test used has correlated the antibody levels 183 with their neutralizing activity, as reported in the methods section. 184 Overall, these data suggest that increased antibody response in patients with anosmia/dysgeusia 185 may be linked to persistence of the virus in the olfactory bulb which through local inflammation 186 and release of antigens, maintains and boosts the antibody response. This study opens new 187 perspectives on the immunity to SARS-CoV-2 and warrants further investigation on the role of 188 anosmia/dysgeusia on antibody response through the design of prospective observational studies 189 coupling the testing of SARS-CoV-2 persistence in the olfactory bulb, loss of smell or taste and 190 antibody titers. In addition, we show that the antibody response to the natural infection is durable 191 and persists for at least 8 months. If the antibody response elicited by the vaccines is similarly 192 effective, we may expect it to last for at least the same amount of time. Further, this observation 193 strongly supports our findings and those of others that convalescent symptomatic COVID-19 patients should receive only one dose of vaccine <sup>18, 19, 20, 21</sup> and suggests that this may occur even at 194

## Methods

boosted.

195

196

197198

- 199 Study population
- 200 This observational study has been approved by the international review board of Istituto Clinico

months of distance from developing the disease as their antibody response will just need to be

- 201 Humanitas for all participating institutes (clinicaltrial.gov NCT04387929). Accrual was on a
- voluntary basis: it started on April 28<sup>th</sup> and more than 80% of personnel participated (n = 4735).
- The study foresees 4 blood collections every 3/4 months. 10 different centers participate: Istituto
- 204 Clinico Humanitas (ICH), Rozzano (MI); Humanitas Gavazzeni, Bergamo; Humanitas Castelli,
- Bergamo; Humanitas Mater Domini (HMD), Castellanza (VA); Humanitas Medical Center, HMC,
- Varese; Humanitas University, Pieve Emanuele (MI); Humanitas San Pio X, Milano; Humanitas
- 207 Cellini, Torino; Humanitas Gradenigo, Torino; Clinica Fornaca, Torino. All participants signed an
- informed consent and filled a questionnaire before blood collection. We analyzed 93 features (72
- 209 categorical and 17 numerical and 4 temporal) including, age, sex, location, professional role, time
- between sample collections, COVID-19 symptoms (fever, sore throat, cough, muscle pain, asthenia,
- anosmia/dysgeusia (loss of smell and taste), gastrointestinal symptoms, conjunctivitis, dyspnea,

chest pain, tachycardia, pneumonia), home exits and smart-working, comorbidities (diabetes, asthma, neoplasia, autoimmunity, cardiovascular disorders, hepatic disorders). We considered "asymptomatics" subjects without any symptoms; "paucisymptomatics" individuals that developed 1 or 2 symptoms; "symptomatics" individuals with more than 3 symptoms. None of the participants were enrolled at the time of symptoms. Thus, when the serological test was performed, they were either asymptomatics or the symptoms had disappeared. After excluding for employees that became positive for SARS-CoV-2 IgG (n = 2) during the observation period and those that dropped from phase 1 or for which we were missing at least two features, we analyzed 4534 participants (4.25% drop out). Here we show the results of the end of phase 2 and phase 3 (second and third blood sampling).

IgG measure

212

213

214

215

216

217

218

219

220

221

222223

239

241

242243

224 For the determination of IgG anti SARS-CoV-2, the Liaison SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Saluggia (VC), Italy) was used <sup>22</sup>. The method is an indirect chemiluminescence 225 226 immunoassay for the determination of anti-S1 and anti-S2 specific antibodies. According to kit 227 manufacturer, the test discriminates among negative (< 15 AU/mL; with 3.8 as the limit of IgG 228 detection) and positive (≥ 15 AU/mL) subjects. We considered positive subjects with IgG plasma 229 levels  $\geq 12$  AU/mL rather than those with IgG  $\geq 15$  AU/mL, as suggested by the test manufacturer, based on our previous publication showing that these two groups behaved very similarly <sup>4</sup>. In 230 231 addition, we considered also individuals with IgG comprised between 3.8 and 12 AU/mL (which 232 we called IgG med: 3.8 < IgG < 12 AU/mL). Consistency and reproducibility of the antibody test in 233 samples collected in the two time points was confirmed for a limited number of individuals (n = 50)234 displaying different degrees of IgG positivity. The LIAISON assay's performance in comparison to a microneutralization assay is shown in Bonelli et al. <sup>22</sup>. The LIAISON serological S1/S2 assay can 235 236 distinguish between neutralization positive and negative samples at cut-offs near 15 AU/mL, and 237 additionally the data indicate that 92% of the samples with >80 AU/mL had neutralization 238 titers  $\ge 1:80$ , while 87% of samples with >80 AU/mL had neutralization titers  $\ge 1:160$ .

from the phase 1 with the detection kits of phase 1 and phase 2 and demonstrated that the tested IgG

As the samples were analyzed in separate batches, we compared the test accuracy on 21 samples

were almost over-imposable (Suppl. Fig. 3).

Statistical analysis and model

- We first cleared the dataset by eliminating data from all of those subjects that did not develop an
- IgG response over time (IgG  $\leq$  3.8 at the beginning and at the end of the examination) (n = 2981).
- We then analyzed the rate of antibody response defined as:
- 248  $RATE = IgG \ phase \ II IgG \ phase \ I = [AU/mL * day]$
- 249  $\Delta days$

250

- 251 Positive rates mean increased antibody response, while negative rates indicate reduction of antibody
- response between the two analyzed time points.
- 253 For statistical analysis, we performed both a univariate and a multivariate analysis. We applied
- Wilcoxon-Mann-Whitney statistical non-parametric test to compare the antibody rate distribution
- between classes of subjects (Table 1 and Table 2).
- We analyzed the distribution of the rate feature and found a high value of kurtosis (461) around the
- 257 median value of 0.016, hence to perform a multivariate analysis we restricted the data set to
- subjects with IgG rates either below the 10<sup>th</sup> percentile or above the 90<sup>th</sup> percentile to prevent a
- 259 bias-variance problem in machine learning models and subjected the data to a linear regression
- analysis between the training and test data sets, where the target variable (rate of antibodies) was
- standardized using the Yeo-Johnson method <sup>23</sup>. We then applied Chi-squared statistical test to
- evaluate differences between classes and the rate thresholds described above (Tables 3 and 4). In
- order to evaluate the possible interactions between features and the rate of antibody response, we
- 264 developed a multivariate approach to perform a binary classification between subjects who
- 265 increased or decreased the level of antibodies. A set of 7 logistic regressions has been applied on
- data using a bootstrap procedure (samples are drawn with replacement) and the output of each
- 267 classifier has been averaged by a Bagging classifier to obtain the final output. The selection of
- hyperparameters of the machine learning model and the feature selection has been performed with a
- 269 Bayesian optimization approach based on cross validation (4 folds, stratified by outcome). The
- 270 comparisons shown in Figure 2 and Suppl. Fig. 2 were carried out using one-tailed Wilcoxon
- 271 matched-pairs signed rank test. A probability value of P < 0.05 was considered significant. Data
- analyses were carried out using GraphPad Prism version 8 and Python version 3.8 with the
- 273 following libraries: Pandas (version 1.1.4, data wrangling), Scipy (version 1.3.2, statistical
- analysis), Scikit-Learn (version 0.24.1, LR statistical model).

## Data and code availability

278

279

280

281282

283

284

285

286

287

288

289

290

291292

293

294

295

296

297

298

299

300

301

302303

Humanitas metadata are deposited in Institutional Zenodo community named IRCCS Humanitas Research Hospital & Humanitas University. The dataset and the code are available at the link https://zenodo.org/record/4528974#.YCONKXnSJaQ with restricted license however available upon request. References Acknowledgments This work was partially supported by a philantropic donation by Dolce & Gabbana, by the Italian Ministry of Health (Ricerca corrente) and by Fondazione Humanitas per la Ricerca. We would like to thank all the employees that volunteered to participate to this study, all the nurses and personnel that collected the samples and the laboratory technicians that run the serological and rinopharyngeal tests. We would also like to thank the Humanitas management and staff, Drs Patrizia Meroni, Michele Lagioia and Michele Tedeschi, who warmly supported this study for the safety of the employees. **Author contribution** R.L. and L.U.: performed data analysis; C.P.: contributed to data analysis and manuscript writing; G.A. and V.S.: contributed to data analysis; M.T.S.: coordinated and supervised the laboratory analyses; E.A.: coordinated the recruitment and sampling of subjects (project administration) and participated in clinical study design; M.S.: carried out the laboratory analyses; A.M.: conceptualization and funding acquisition; M.R.: conceived the study, analyzed the data and wrote the manuscript. **Competing interests** The authors declare no competing interests.

## **Tables**

304

305

## Table 1. Demographic distribution of antibody rates.

		counts	min	25 perc	50 perc	75 perc	max	mean	St.Dev.	p_value a
a	F	1105	-3.39	-0.04	-0.02	0.02	16.32	0.07	0.61	0.0120
Sex	M	448	-0.88	-0.04	-0.02	0	10.37	0.03	0.53	0.0139
	21-30	300	-3.39	-0.04	-0.02	0.01	4.51	0.03	0.41	0.2644
	31-40	365	-0.92	-0.04	-0.02	0.01	2.26	0.02	0.21	0.2302
Age	41-50	455	-2.49	-0.04	-0.02	0.03	3.11	0.06	0.37	0.1083
	51-60	309	-0.88	-0.04	-0.01	0.02	16.32	0.1	0.96	0.1442
	60+	124	-0.68	-0.04	-0.02	-0.01	10.37	0.12	0.99	0.0586
	18.5≤ BMI <25	940	-0.92	-0.04	-0.02	0.01	10.37	0.03	0.41	0.3821
DMI	BMI ≥ 30	106	-3.39	-0.05	-0.02	0.14	16.32	0.23	1.69	0.2182
BMI b	25≤ BMI <30	347	-0.57	-0.04	-0.02	0.01	3.11	0.05	0.29	0.3933
	BMI < 18.5	73	-0.22	-0.04	-0.02	0.02	1.27	0.05	0.26	0.3959
I C 1	IgG ≥ 12	613	-3.39	-0.08	0.02	0.23	16.32	0.18	0.92	2.1 E-10
IgG class phase 1	$IgG \le 3.8$	74	0.01	0.01	0.02	0.03	0.08	0.02	0.01	1.5 E-15
phase 1	3.8 < IgG < 12	866	-0.13	-0.03	-0.02	-0.01	0.83	-0.02	0.04	8.0 E-22
	Other c	200	-0.57	-0.04	-0.02	-0.01	16.32	0.09	1.17	0.0116
	Anesthesiologist	19	-0.83	-0.04	-0.02	0.01	0.09	-0.05	0.2	0.4305 b
Role	Biologist	18	-0.18	-0.05	-0.02	-0.02	0.03	-0.04	0.05	0.0978 b
	Surgeon	67	-0.88	-0.05	-0.02	0.07	0.61	0.02	0.21	0.2653
	Physiotherapist	21	-0.12	-0.04	-0.02	0.01	0.35	0.01	0.1	0.4204
	Nurse	398	-3.39	-0.04	-0.02	0.04	3.11	0.08	0.41	0.0581
	Physician	210	-0.92	-0.04	-0.01	0.02	10.37	0.08	0.75	0.0804
	Healthcare Partner Operator	149	-2.49	-0.03	-0.01	0.17	1.55	0.1	0.38	0.0009
	Front office (PARC)	108	-0.32	-0.04	-0.02	0.01	2.55	0.03	0.27	0.2892
	Researcher	50		-0.03	-0.02	-0.01	4.51	0.06	0.68	0.1514
	Cleaning service	29		-0.03	-0.02	0.03	1.72	0.09	0.41	0.2414
	Transport service	14			-0.01	0.02	2.22	0.13	0.62	0.4359 b
	Staff	188	-0.4	-0.04	-0.02	-0.01	0.98	0	0.15	0.0026
	Student	20	-0.19	-0.03	-0.02	-0.01	0.21	-0.02	0.08	0.3705 b
	Laboratory technician	31		-0.03	-0.01	-0.01	0.51	0.02	0.15	0.3243
	Radiology technician	31		-0.03	-0.02	0.01	1.01	0.04	0.22	0.4002
Site	Other <sup>c</sup>	21		-0.04	-0.02	-0.01	2.22	0.08	0.49	0.2080
	Casa di Cura Cellini	51	-0.17	-0.05	-0.03	-0.01	1.27	0.01	0.22	0.0111
	Clinica Fornaca di Sessant	47	-0.4	-0.05	-0.03	0	0.53	0	0.15	0.0833
	Humanitas Castelli	87	-0.28	-0.04	0.02	0.21	3.11	0.24	0.62	4.7 E-05
	Humanitas Gavazzeni	313	-0.88	-0.04	-0.01	0.15	10.37	0.13		0.0001
	Humanitas Gradenigo	109	-2.49	-0.04	-0.02	-0.01	0.67	-0.01	0.27	0.0586
	Humanitas Mater Domini	105	-0.17	-0.03	-0.02	-0.01	0.63	0	0.1	0.3412
	Humanitas Medical Care	23	-0.19	-0.04	-0.02	-0.01	0.02	-0.03	0.04	0.0969
	Humanitas Rozzano		-3.39		-0.02	0	16.32	0.04	0.7	0.0338
	Humanitas San Pio X	98	-0.68	-0.03	-0.02	0	2.39	0.04	0.29	0.2968
a <b>xx</b> 7:1	Humanitas University	32	-0.2	-0.04	-0.02	-0.01	0.19	-0.03	0.08	0.0590

<sup>&</sup>lt;sup>a</sup> = Wilcoxon-Mann-Whitney test

<sup>&</sup>lt;sup>b</sup> = Some subjects did not indicate their BMI

<sup>&</sup>lt;sup>c</sup> = Refers to volunteers and other professionals that operate in several structures

d = Minority class is less or equal to 20 (Wilcoxon-Mann-Whitney test is not reliable)

## Table 2. Antibody rates according to symptoms.

			counts	min	25 perc	50 perc	75 perc	max	mean	St. Dev.	p_value a
Class symptoms	Asymptomatic		91	-1.5	-0.13	-0.05	0.09	2.39	0.04	0.5	0.00003
phase 1 (subjects with IgG ≥ 12)	Paucisymptomat	ic	203	-3.39	-0.08	0.02	0.21	4.51	0.14	0.56	0.32865
with igo <u>&gt; 12)</u>	Symptomatic		319	-2.49	-0.06	0.07	0.28	16.32	0.24	1.16	0.00057
	Fever	No	350	-3.39	-0.09	0.01	0.21	4.51	0.13	0.02725	0.02725
	10001	Yes	263	-2.49	-0.06	0.05	0.25	16.32	0.24		0.02723
	Low-grade fever	No	481	-3.39	-0.08	0.02	0.23	16.32	0.19	0.17265	0.17265
	Low-grade level	Yes	132	-0.39	-0.07	0.05	0.26	2.55	0.14		0.17203
	Cough	No	372	-3.39	-0.08	0.01	0.19	16.32	0.14	0.01120	0.01120
	Cough	Yes	241	-2.49	-0.07	0.07	0.31	10.37	0.24		0.01120
	Sore throath	No	353	-3.39	-0.09	0.02	0.23	16.32	0.19	0.08309	0.08309
	Sole ulloaui	Yes	260	-2.49	-0.07	0.04	0.25	4.51	0.16		0.08309
	Muscle pain	No	299	-1.5	-0.1	0	0.2	4.51	0.13	0.00763	0.00763
		Yes	314	-3.39	-0.06	0.06	0.27	16.32	0.22		
	Asthenia	No	341	-3.39	-0.1	0	0.21	16.32	0.17	0.00574	0.00574
Symptoms phase 1 (subjects with		Yes	272	-2.49	-0.06	0.07	0.25	10.37	0.19		
	Anosmia / dysgeusia	No	313	-3.39	-0.12	-0.01	0.2	16.32	0.14	0.00006	0.00006
$IgG \ge 12$ )		Yes	300	-0.86	-0.05	0.06	0.28	10.37	0.22		
180 = 12)	Gastrointestinal symptoms	No	403	-3.39	-0.08	0.03	0.21	10.37	0.17	0.46477	0.46477
		Yes	210	-2.49	-0.08	0.02	0.25	16.32	0.19		
	Conjunctivitis	No	517	-3.39	-0.08	0.02	0.21	16.32	0.18	0.16050	0.16050
		Yes	96	-2.49	-0.07	0.04	0.32	1.72	0.14		0.16050
	Dyannaa	No	493	-3.39	-0.08	0.02	0.23	16.32	0.16	0.34700	0.34700
	Dyspnea	Yes	120	-2.49	-0.07	0.05	0.26	10.37	0.24		
	Chact nain	No	502	-3.39	-0.08	0.01	0.24	10.37	0.15	0.08088	0.08088
		Yes	111	-0.39	-0.04	0.07	0.22	16.32	0.3		
	Tachycardia Y	No	512	-3.39	-0.08	0.01	0.21	4.51	0.13	0.02353	0.02353
		Yes	101	-2.49	-0.06	0.08	0.32	16.32	0.4		
	Province	No	568	-3.39	-0.08	0.02	0.22	16.32	0.15	0.18692	0.1070
	Pneumonia $\frac{1}{Y}$		45	-0.88	-0.06	0.06	0.38	10.37	0.51	1.69	0.18692
a = Wilcoxon-Mar	nn-Whitney test										

## Table 3. Chi-squared analysis of groups < 10<sup>th</sup> percentile and > 90<sup>th</sup> percentile.

326

Age			< 10 perc	> 90 perc	p_value
Age	Cov	F	321	340	0.0627
Age	Sex	M	133	105	0.0627
Age		21-30	93	83	0.5429
Sing		31-40	108	94	0.3804
BMI a   18.5≤ BMI <25   267   255   0.690	Age	41-50	121	142	0.0970
BMI a BMI ≥ 30		51-60	88	98	0.3711
BMI a   BMI ≥ 30   58   72   0.17s		60+	44	28	0.0793
BMI   a   25 \leq BMI \leq 30   106   93   0.42     BMI \leq 18.5   23   25   0.82     Other   63   37   0.010     Anesthesiologist   6   7   0.970     Biologist   5   2   0.46     Surgeon   25   21   0.700     Physiotherapist   6   7   0.97     Nurse   113   132   0.12     Physician   56   61   0.600     Healthcare Partner Operator   38   64   0.000     Front office (PARC)   31   28   0.84     Researcher   13   9   0.54     Cleaning service   7   9   0.76     Transport Service   5   5   0.774     Staff   69   44   0.02     Student   5   4   0.975     Laboratory Technician   6   7   0.970     Radiology Technician   6   8   0.750     Clinica Fornaca di Sessant   18   12   0.38     Humanitas Castelli   23   47   0.000     Humanitas Gavazzeni   97   142   0.000     Humanitas Gradenigo   36   22   0.09     Humanitas Mich Participate   10   10   10     Clinica Michael Participate   10   10     Humanitas Gradenigo   36   22   0.09     Humanitas Michael Participate   10   10     Clinica Fornaca di Sessant   18   12   0.38     Humanitas Gradenigo   36   22   0.09     Humanitas Gradenigo   36   22   0.09		18.5≤ BMI <25	267	255	0.6963
BMI	DMI 8	BMI ≥ 30	58	72	0.1750
BMI < 18.5   23   25   0.82c     Other b   63   37   0.01c     Anesthesiologist   6   7   0.97c     Biologist   5   2   0.46c     Surgeon   25   21   0.70c     Physiotherapist   6   7   0.97     Nurse   113   132   0.12c     Physician   56   61   0.60c     Healthcare Partner Operator   38   64   0.00c     Front office (PARC)   31   28   0.84c     Researcher   13   9   0.54c     Cleaning service   7   9   0.76c     Transport Service   5   5   0.774c     Staff   69   44   0.02c     Student   5   4   0.975c     Laboratory Technician   6   7   0.97c     Radiology Technician   6   8   0.75c     Other b   6   3   0.522c     Casa di Cura Cellini   19   8   0.05c     Clinica Fornaca di Sessant   18   12   0.38c     Humanitas Gavazzeni   97   142   0.00c     Site   Humanitas Gradenigo   36   22   0.09c     Humanitas Gradenigo   36   22   0.09c     Humanitas Mater Parisis   10   10.00c     Humanitas Gradenigo   36   22   0.09c     Humanitas Mater Parisis   10   10.00c     Humanitas Gradenigo   36   22   0.09c     Clais Alexandra di Sessant   18   12   0.00c     Humanitas Gradenigo   36   22   0.09c     Clais Mater Parisis   10   10.00c     Humanitas Gradenigo   36   22   0.09c     Clais Mater Parisis   10   10.00c     Clais Mater Parisis   10.00c     Clais Materia Mater Parisis   10.00c     Clais Materia Mat	BMI	25≤ BMI <30	106	93	0.4214
Anesthesiologist			23	25	0.8261
Anesthesiologist   6		Other b	63	37	0.0109
Biologist   5   2   0.466     Surgeon   25   21   0.700     Physiotherapist   6   7   0.97     Nurse   113   132   0.12     Physician   56   61   0.600     Healthcare Partner Operator   38   64   0.000     Front office (PARC)   31   28   0.840     Researcher   13   9   0.540     Cleaning service   7   9   0.760     Transport Service   5   5   0.774     Staff   69   44   0.02     Student   5   4   0.975     Laboratory Technician   6   7   0.970     Radiology Technician   6   8   0.750     Other   6   3   0.522     Casa di Cura Cellini   19   8   0.050     Clinica Fornaca di Sessant   18   12   0.380     Humanitas Gavazzeni   97   142   0.000     Site   Humanitas Gradenigo   36   22   0.090		Anesthesiologist	6	7	0.9701
Physiotherapist		Biologist	5	2	0.4640
Physiotherapist		Surgeon	25	21	0.7007
Nurse		Physiotherapist		7	0.9710
Physician		Nurse	113	132	0.1255
Role         Healthcare Partner Operator         38         64         0.000           Front office (PARC)         31         28         0.849           Researcher         13         9         0.549           Cleaning service         7         9         0.769           Transport Service         5         5         0.774           Staff         69         44         0.02           Student         5         4         0.975           Laboratory Technician         6         7         0.976           Radiology Technician         6         8         0.755           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.055           Clinica Fornaca di Sessant         18         12         0.385           Humanitas Gavazzeni         97         142         0.000           Site         Humanitas Gradenigo         36         22         0.09		Physician	56	61	0.6082
Front office (PARC)   31   28   0.84     Researcher   13   9   0.54     Cleaning service   7   9   0.76     Transport Service   5   5   0.774     Staff   69   44   0.02     Student   5   4   0.975     Laboratory Technician   6   7   0.976     Radiology Technician   6   8   0.75     Other b   6   3   0.522     Casa di Cura Cellini   19   8   0.05     Clinica Fornaca di Sessant   18   12   0.38     Humanitas Castelli   23   47   0.00     Humanitas Gavazzeni   97   142   0.000     Site   Humanitas Gradenigo   36   22   0.09     Humanitas Gradenigo   36   22   0.09	-	Healthcare Partner Operator	38	64	0.0062
Researcher         13         9         0.54           Cleaning service         7         9         0.76           Transport Service         5         5         0.774           Staff         69         44         0.02           Student         5         4         0.975           Laboratory Technician         6         7         0.976           Radiology Technician         6         8         0.75           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.05           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gradenigo         36         22         0.09	Role	Front office (PARC)	31	28	0.8494
Cleaning service         7         9         0.769           Transport Service         5         5         0.774           Staff         69         44         0.02           Student         5         4         0.975           Laboratory Technician         6         7         0.976           Radiology Technician         6         8         0.755           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.055           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.000           Humanitas Gradenigo         36         22         0.09		Researcher	13		0.5485
Transport Service         5         5         0.774           Staff         69         44         0.02           Student         5         4         0.975           Laboratory Technician         6         7         0.976           Radiology Technician         6         8         0.75           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.05           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gradenigo         36         22         0.09		Cleaning service	7		0.7698
Staff         69         44         0.02           Student         5         4         0.975           Laboratory Technician         6         7         0.976           Radiology Technician         6         8         0.755           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.055           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.000           Humanitas Gradenigo         36         22         0.09		Transport Service	5	5	0.7747 °
Student         5         4         0.975           Laboratory Technician         6         7         0.976           Radiology Technician         6         8         0.75           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.05           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gavazzeni         97         142         0.00           Site         Humanitas Gradenigo         36         22         0.09		Staff	69	44	0.0214
Radiology Technician   6   8   0.753		Student	5	4	0.9759°
Radiology Technician         6         8         0.75           Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.05           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gavazzeni         97         142         0.00           Site         Humanitas Gradenigo         36         22         0.09		Laboratory Technician	6	7	0.9701
Other b         6         3         0.522           Casa di Cura Cellini         19         8         0.05           Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gavazzeni         97         142         0.00           Site         Humanitas Gradenigo         36         22         0.09		Radiology Technician	6	8	0.7587
Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gavazzeni         97         142         0.00           Site         Humanitas Gradenigo         36         22         0.09		Other <sup>b</sup>	6	3	0.5223 °
Clinica Fornaca di Sessant         18         12         0.38           Humanitas Castelli         23         47         0.00           Humanitas Gavazzeni         97         142         0.00           Site         Humanitas Gradenigo         36         22         0.09		Casa di Cura Cellini	19	8	0.0573
Humanitas Castelli         23         47         0.000           Humanitas Gavazzeni         97         142         0.000           Site         Humanitas Gradenigo         36         22         0.09		Clinica Fornaca di Sessant	18	12	0.3828
Humanitas Gavazzeni         97         142         0.000           Site         Humanitas Gradenigo         36         22         0.09		Humanitas Castelli			0.0032
Site Humanitas Gradenigo 36 22 0.09		Humanitas Gavazzeni	97	142	0.0005
Hamanitas Matan Damini	Site	Humanitas Gradenigo	36	22	0.0918
		Humanitas Mater Domini		23	0.7041
H : M !! 10		Humanitas Medical Care	8		0.2379°
II ' D		Humanitas Rozzano	190	160	0.0806
H '' G D' V		Humanitas San Pio X	27	21	0.5025
77		Humanitas University	10	4	0.1905 °

<sup>&</sup>lt;sup>a</sup> = Some subjects did not indicate their BMI

b = Refers to volunteers and other professionals that operate in several structures

<sup>&</sup>lt;sup>c</sup> = Minority class is less or equal to 5 (chi-square test is not reliable)

# Table 4. Chi-squared analysis of groups $< 10^{th}$ percentile and $> 90^{th}$ percentile per symptoms.

329

			<10 perc	>90perc	p_value	% Yes<10 perc <sup>a</sup>	%Yes>90perc
	Fever	No	360	284	3.9E-07		
		Yes	94	161		37	63
	Low-grade fever	No	388	359	0.0678	42	
		Yes	66	86		43	57
	Cough	No	335	284	0.0016		50
	- C	Yes	119	161		43	58
	Sore throath	No	302	271	0.0923	47	50
		Yes	152	174		47	53
	Muscle pain	No	310 144	246 199	0.0001	42	58
	_	Yes				42	38
	Asthenia	No	340	268 177	3.7E-06	39	C1
		Yes	114			39	61
	Anosmia/dysgeusia	No Yes	364 90	247 198	4.0E-15	31	69
Crimentonia	Ctitti1	No	336			31	09
Symptoms	Gastrointestinal	Yes	118	313 132	0.2485	47	53
	symptoms	No	400	382		4/	33
	Conjunctivitis	Yes	54	63	0.3633	46	54
		No	405	375		40	34
	Dyspnea	Yes	403	70	0.0370	41	59
		No	415	367		41	39
	Chest pain	Yes	39	78	0.0001	33	67
		No	406	371		33	07
	Tachycardia	Yes	48	74	0.0107	39	61
		No	440	420		39	01
	Pneumonia	Yes	14	25	0.0889	36	64
		Asymptomatic	150	80	3.4E-07	65	35
	Total of Symptoms in phase I	Paucisymptomatic	179	158	0.2520	53	47
		Symptomatic	125	207	5.6E-09	38	62
	Chronic Obstructive	No	451	444		30	02
	Bronchopneumopathy	Yes	3	1	0.6305 b		
	Asthma  Dyslipidemia	No	430	412			
		Yes	24	33	0.2408		
		No	413	404			
		Yes	41	41	0.9834		
		No	431	438			
	Past Neoplasia	Yes	23	7	0.0063		
		No	401	409			
	Hypertension	Yes	53	36	0.0915		
	Past	No	454	443	h		
	Coronaropathies	Yes	0	2	0.4702 <sup>b</sup>		
		No	450	441	h		
	Atrial Fibrillation	Yes	4	4	0.7439 <b>b</b>		
		No	452	445	h		
Comorbidities	Past Stroke/ TIA	Yes	2	0	0.4878 <sup>b</sup>		
		No	448	444	h		
	Steatosis/Cyrrosis	Yes	6	1	0.1359 <b>b</b>		
	Chronic kidney	No	453	445			
	failure	Yes	1	0	0.9920 <sup>b</sup>		
		No	452	441	h		
	Other liver diseases	Yes	2	4	0.6641 <b>b</b>		
	Rheumatological	No	445	431	_		
	diseases	Yes	9	14	0.3715		
	Other diseases	No	418	409			
	of the immune system	Yes	36	36	0.9726		
		No	452	443	ı.		
	Diabetes mellitus	Yes	2	2	0.6305 <b>b</b>		
		No	452	445			
	Gotta	Yes	2	0	0.4878 <b>b</b>		
		1 03		U			
· Percentage of and	bjects with symptoms (	Vec) per rete class					

## Figure legends

- Figure 1: a, Dataset < 10<sup>th</sup> percentile Regression Diagnostic plot of amount of IgG after Yeo-
- Johnson normalization against residuals of training and test data; **b**, Dataset >90<sup>th</sup> percentile
- 337 Regression Diagnostic plot of amount of IgG after Yeo-Johnson normalization against residuals of
- training and test data; c, Barplot with Logistic Regression coefficients for most important features;
- 339 **d**, Odds ratio of Logistic Regression with confidence intervals (95%) for the most important
- 340 features.

333

334

341

- Figure 2: Anti-Spike S1/S2 IgG plasma levels in asymptomatics (n=61), paucisymptomatics
- 343 (n=163) and symptomatics (n=275) measured at three different time points (phase 1-3). Each dot
- 344 corresponds to an individual subject. Log scale on Y axis. The box plots show the interquartile
- 345 range, the horizontal lines show the median values and the whiskers indicate the minimum-to-
- maximum range. P values were determined using one-tailed Wilcoxon matched-pairs signed rank
- 347 test.

348

349

350

## References

- Dan JM, *et al.* Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **371**, (2021).
- Ward H, *et al.* Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. *medRxiv*, 2020.2010.2026.20219725 (2020).
- 355 3. Long QX, *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* **26**, 1200-1204 (2020).
- 357 4. Sandri MT, *et al.* SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. *Sci Rep* **11**, 12312 (2021).
- Carfi A, Bernabei R, Landi F, Group ftGAC-P-ACS. Persistent Symptoms in Patients After
   Acute COVID-19. *JAMA* 324, 603-605 (2020).
- 361 6. Butowt R, von Bartheld CS. Anosmia in COVID-19: Underlying Mechanisms and
- Assessment of an Olfactory Route to Brain Infection. *Neuroscientist*, 1073858420956905 (2020).
- 7. Lechien JR, *et al.* Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. *J Intern Med* **288**, 335-344 (2020).
- Kumar N, Bhartiya S, Desai S, Mutha A, Beldar A, Singh T. Seroprevalence of Antibodies
   Against SARS-CoV-2 Among Health Care Workers in Mumbai, India. *Asia Pac J Public Health*, 1010539520977307 (2020).
- 9. Pierron D, *et al.* Smell and taste changes are early indicators of the COVID-19 pandemic and political decision effectiveness. *Nat Commun* **11**, 5152 (2020).

- 371 10. Brann DH, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory
- 372 system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 6, (2020).
- 373 11. De Melo GD, et al. COVID-19-related anosmia is associated with viral persistence and
- inflammation in human olfactory epithelium and brain infection in hamsters. *Sci Transl Med*, (2021).
- Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2
   Entry Proteins, ACE2 and TMPRSS2, in Cells of the Olfactory Epithelium: Identification of
- 378 Cell Types and Trends with Age. ACS Chem Neurosci 11, 1555-1562 (2020).
- 379 13. Chen M, *et al.* Elevated ACE-2 expression in the olfactory neuroepithelium: implications 380 for anosmia and upper respiratory SARS-CoV-2 entry and replication. *Eur Respir J* **56**,
- 381 (2020).
- 382 14. Politi LS, Salsano E, Grimaldi M. Magnetic Resonance Imaging Alteration of the Brain in a
- 383 Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. *JAMA Neurol* **77**, 1028-384 1029 (2020).
- Tsivgoulis G, *et al.* Olfactory bulb and mucosa abnormalities in persistent COVID-19-induced anosmia: a magnetic resonance imaging study. *Eur J Neurol*, (2020).
- 387 16. Laurendon T, *et al.* Bilateral transient olfactory bulb edema during COVID-19-related anosmia. *Neurology* **95**, 224-225 (2020).
- Yan CH, Prajapati DP, Ritter ML, DeConde AS. Persistent Smell Loss Following
   Undetectable SARS-CoV-2. *Otolaryngol Head Neck Surg* 163, 923-925 (2020).
- 391 18. Krammer F, *et al.* Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**, 1372-1374 (2021).
- 393 19. Saadat S, *et al.* Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. *JAMA* **325**, 1467-1469
- 395 (2021).

- 396 20. Abu Jabal K, et al. Impact of age, ethnicity, sex and prior infection status on
- immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-
- world evidence from healthcare workers, Israel, December 2020 to January 2021. *Euro Surveill* **26**, (2021).
- 400 21. Levi R, *et al.* One dose of SARS-CoV-2 vaccine exponentially increases antibodies in recovered individuals with symptomatic COVID-19. *J Clin Invest*, (2021) in press.
- 402 22. Bonelli F, et al. Clinical And Analytical Performance Of An Automated Serological Test
- That Identifies S1/S2 Neutralizing IgG In COVID-19 Patients Semiquantitatively. *J Clin Microbiol*, (2020).
- 405 23. Yeo IK, Johnson RA. A new family of power transformations to improve normality or symmetry. *Biometrika* **87**, 954-959 (2000).





